| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Abiraterone Acetate |
| Brand | Zytiga® |
| Indication | Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 21/10/2011 |
| Rapid review completed | 02/11/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full submission received from Applicant | 12/12/2011 |
| NCPE assessment completed | 22/05/2012 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
May 2014
The HSE has approved reimbursement following confidential price negotiations.
